The Future of DLBCL: Innovations in Therapy and Patient Care

April 7, 2025

By Krish Patel, MD
Saurabh Dahiya, MD, FACP

Opinion

Video

Panelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.

EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy

EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL

EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL

EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection

EP: 7.Personalizing CAR T: Making the Right Call for Each Patient

EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL

EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?

EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

Now Viewing

EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care

Video content above is prompted by the following:

How do you envision the treatment landscape evolving over the next few years as we integrate novel chimeric antigen receptor T-cell approaches with other available therapies?
What excites you most about the future of cellular therapy in diffuse large B-cell lymphoma based on the research and clinical advances discussed at Tandem 2025?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!